Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target lifted by stock analysts at JPMorgan Chase & Co. from ...

Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Gilead Sciences ...

Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences GILD. And retail traders should know.

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $130.00.

In the BOH series What I Love, we’re asking designers to build us a mood board of what’s inspiring them right now. Jennie ...

Shares of Gilead Sciences, Inc. GILD were down 2.47% after the Wall Street Journal reported that The Health and Human ...

Pharmaceutical stock Gilead Sciences Inc (NASDAQ:GILD) is down 2.6% at $107.34, after news that domestic HIV prevention is ...

Gilead Sciences (GILD) stock fell after The Wall Street Journal reported that the Health and Human Services Department is looking at ...

Shares of Gilead Sciences (NASDAQ: NASDAQ:GILD) fell 3.4% following a recent Wall Street Journal report indicating that the ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

We recently published a list of 13 Most Undervalued NASDAQ Stocks To Buy According To Hedge Funds. In this article, we are going to take a look at where Gilead Sciences, Inc.